Whole-genome sequencing has identified potential genetic explanations for recurrent pregnancy loss (RPL) in nearly one-quarter of families with unexplained miscarriages, providing new insights into the genetic basis of this reproductive condition. In a study involving 118 families with recurrent chromosomally normal pregnancy losses, pathogenic or likely pathogenic variants were identified in 18 families (15.3%), while another 12 (10.2%) carried variants of uncertain significance (VUS). Published in Genome Medicine, the findings highlight the contribution of inherited genetic variations to pregnancy loss and the potential role of genomic testing in reproductive counselling.
RPL, generally defined as two or more miscarriages, affects approximately 5% of couples. Nearly 70% of cases involve pregnancies with normal chromosomal findings, leaving many families without an identifiable explanation despite conventional investigations. To investigate possible genetic causes, researchers performed whole-genome sequencing of both parents and products of conception (POC). The study initially enrolled 176 families across five academic centres between 2022 and 2024. After excluding samples with chromosomal abnormalities or inadequate DNA quality, 118 families were included in the final analysis. Approximately 79% of pregnancy losses occurred during the first trimester, while 95% showed no structural abnormalities on prenatal ultrasonography. The family-based approach enabled the identification of inherited and newly occurring genetic variations and assessment of their potential clinical significance.
The analysis identified variants across 28 genes, including 13 previously associated with fetal or neonatal mortality and 15 not previously reported in association with pregnancy loss. Most variants were inherited, with at least one parent carrying the implicated genetic change in 24 of the 30 families. Biallelic inheritance, involving alterations in both copies of a gene, was the most frequently observed pattern, occurring in 11 families. Although individuals carrying a single altered copy may remain unaffected, embryos inheriting pathogenic variants from both parents may develop severe abnormalities affecting pregnancy survival.
One notable finding involved DHCR7, which encodes an enzyme involved in cholesterol biosynthesis. Biallelic pathogenic variants in this gene cause Smith-Lemli-Opitz syndrome, a condition associated with developmental abnormalities. A pregnancy loss at 12 weeks in a family carrying variants in both copies of DHCR7 suggested a possible association with early pregnancy loss.
Other genetic mechanisms included X-linked inheritance and parental mosaicism. In five families, inherited X-chromosome variants were identified in male embryos, while two families demonstrated parental mosaicism, in which genetic variations were present in only a proportion of cells, potentially including reproductive cells. The findings also suggested that inherited variants could have different clinical consequences in parents and their offspring, with apparently healthy parents transmitting genetic changes associated with severe embryonic outcomes.
Importantly, additional POC samples from three families revealed different genetic findings, indicating that multiple mechanisms may contribute to RPL within the same family. The investigators also identified variants involving HNRNPK in an eight-week pregnancy loss and PRF1 in a 28-week loss. These genes are involved in RNA processing and immune-cell cytotoxic activity, respectively, suggesting possible associations between affected biological pathways and the timing of pregnancy loss.
The findings suggest that sequencing parental genomes alongside POC samples could complement conventional chromosomal investigations in selected cases of unexplained RPL. Identification of confirmed pathogenic variants may help establish a diagnosis, clarify inheritance patterns, estimate recurrence risks and improve reproductive counselling. For couples undergoing in vitro fertilisation, preimplantation genetic testing for monogenic conditions may be considered when a confirmed disease-associated variant is identified.
However, VUS and newly proposed gene–disease associations require further validation and should not independently guide embryo selection or clinical management. Additional family recruitment and genetic validation are ongoing to establish the clinical significance of the findings. Overall, the study highlights the potential of family-based genomic testing to identify previously unrecognised genetic causes of RPL and support more individualised reproductive counselling and pregnancy planning.
Reference
- Aminbeidokhti M, Halstead M, Rodriguez-Escriba M, Tise CG, Bernstein JA, Cakmak H, et al. Genetic variants in recurrent euploid pregnancy loss. Genome Med. 2026;18:179. doi:10.1186/s13073-026-01817-5.